Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mitchell S. Steiner
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 20
- Beta
- -1.16
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -11.50
Financials
Revenue
$0.00-100.0%Net Income
$-6.99MEBITDA
$-6.99M-2681.1%Free Cash Flow
$-5.47MEPS (diluted)
$-0.30Shares Outstanding (diluted)
23.05M-20.4%Operating Expenses
$7.71MCash & Debt
$23.88MReturn of Capital
$0.00Revenue by Segment (annual)
$16.89MDividend per Share
$0.07Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-22.73M | $-1.55 |
| 2024 | $16.89M | $-37.80M | $-2.80 |
| 2023 | $16.30M | $-93.15M | $-10.96 |
| 2022 | $39.35M | $-83.78M | $-10.49 |
| 2021 | $61.26M | $7.39M | $1.00 |
| 2020 | $42.59M | $-18.97M | $-2.84 |
| 2019 | $31.80M | $-12.02M | $-1.90 |
| 2018 | $15.86M | $-23.94M | $-4.44 |
| 2017 | $13.66M | $-6.61M | $-2.48 |
| 2016 | $22.13M | $344.7K | $0.10 |
| 2015 | $32.60M | $4.35M | $1.50 |
| 2014 | $24.49M | $2.43M | $0.90 |
| 2013 | $31.46M | $14.34M | $5.10 |
| 2012 | $35.03M | $15.30M | $5.50 |
Valuation
VERUhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
10-93.33%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·28d ago·Negative
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines' RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial --New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer efficacy (IC50=18.2nM) in daraxonrasib resistant human pancreatic cancer cell line which is a drug concentration that can be achieved with current sabi
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference MIAMI, FL, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell Steiner, M.D.
View source ↗ - Newsseekingalpha.com·56d ago·Positive
Veru Inc. (VERU) Q3 2026 Earnings Call Transcript Veru Inc. (VERU) Q3 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·57d ago·Negative
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients –
View source ↗
Earnings
Thu, Nov 26(in 7 weeks)
Consensus estimate $-0.26 per share
Typical surprise +30.7% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.30 vs $-0.32beat
- Wed, May 13$-0.13 vs $-0.31beat
- Wed, Feb 11$-0.26 vs $-0.47beat
- Wed, Dec 17$0.05 vs $-0.39beat
- Tue, Aug 12$-0.50 vs $-0.55beat
- Thu, May 8$-0.50 vs $-0.60beat
Estimates and results for VERU via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VERU officers and directors.
- Bought
- $193k
- Sold
- $3.2m
8 trades
8 trades
- Barnette K Garybought
- Rankowitz Michael Lbought
- Rankowitz Michael Lbought
- Fisch Harrybought
- Barnette K Garybought
- Steiner Mitchell Shustersold
- Steiner Mitchell Shustersold
- Steiner Mitchell Shustersold
84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VERU.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.